BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), ...
BOSTON/LONDON - Oncology biotechnology company Akari Therapeutics, Plc (NASDAQ:AKTX), currently valued at $32 million, announced Wednesday it has entered into a definitive agreement to raise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback